Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going

Background: Pancreatic ductal adenocarcinoma (PDAC) represents a challenging disease for the surgeon, oncologist, and radiation oncologist in both diagnostic and therapeutic settings. Surgery is currently the gold standard treatment, but the role of neoadjuvant treatment (NAD) is constantly evolving...

Descripción completa

Detalles Bibliográficos
Autores principales: Coppola, Alessandro, Farolfi, Tommaso, La Vaccara, Vincenzo, Iannone, Immacolata, Giovinazzo, Francesco, Panettieri, Elena, Tarallo, Mariarita, Cammarata, Roberto, Coppola, Roberto, Caputo, Damiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253643/
https://www.ncbi.nlm.nih.gov/pubmed/37297872
http://dx.doi.org/10.3390/jcm12113677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253643/
https://www.ncbi.nlm.nih.gov/pubmed/37297872
http://dx.doi.org/10.3390/jcm12113677

Ejemplares similares